SILBER ALLAN C 4
4 · POINT Biopharma Global Inc. · Filed Mar 31, 2022
Insider Transaction Report
Form 4
SILBER ALLAN C
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-03-29+332,476→ 332,476 totalExercise: $8.13Exp: 2028-03-29→ Common Stock (332,476 underlying)
Footnotes (1)
- [F1]The option vests 25% on the first anniversary of the date of grant with the remaining 75% vesting in three equal annual installments thereafter.